[go: up one dir, main page]

CA2364610A1 - Pharmaceutical solubilized in aerosol propellant - Google Patents

Pharmaceutical solubilized in aerosol propellant Download PDF

Info

Publication number
CA2364610A1
CA2364610A1 CA002364610A CA2364610A CA2364610A1 CA 2364610 A1 CA2364610 A1 CA 2364610A1 CA 002364610 A CA002364610 A CA 002364610A CA 2364610 A CA2364610 A CA 2364610A CA 2364610 A1 CA2364610 A1 CA 2364610A1
Authority
CA
Canada
Prior art keywords
ingredient
intermediate formulation
acid
formulation
pharmaceutical agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002364610A
Other languages
French (fr)
Other versions
CA2364610C (en
Inventor
Pankaj Modi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generex Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/272,563 external-priority patent/US6350432B1/en
Application filed by Individual filed Critical Individual
Publication of CA2364610A1 publication Critical patent/CA2364610A1/en
Application granted granted Critical
Publication of CA2364610C publication Critical patent/CA2364610C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A formulation with a pharmaceutical agent solubilized in a propellant can be administered buccally or into the lungs using a metered dose spray applicator. The pharmaceutical agent is dispensed from a pressurized container containing a stable solubilized mixture of propellant which is liquid under pressure and an intermediate formulation.
The intermediate formulation comprises the proteinic pharmaceutical agent, water, first ingredient, second ingredient and at least one third ingredient. The first ingredient is glycerin and/or polyglycerin in an amount of from 1-50 wt./wt.% of the intermediate formulation. The second ingredient is phenol and/or methyl phenol in an amount of from 1-20 wt./wt.% of the intermediate formulation. Each third ingredient is selected from the group consisting of alkali metal C8 to C22 alkyl sulphate, polidocanol C6 to C40 alkyl ethers, trihydroxy sodium oxo-cholanyl glycines, polyoxyethylene sorbitanethers, alkyl-aryl polyether alcohols, hyaluronic acid and pharmaceutically suitable salts thereof, monoolein, triolein, lysine, polylysine, oleic acid, linoleic acid, linolenic acid, monooleates and laurates, glycolic acid, lactic acid, chenodeoxycholate, deoxycholate, chamomile extract, cucumber extract, borage oil and evening of primrose oil and mixtures thereof, in an amount of from 1-50 wt./wt.% of the intermediate formulation. The total concentration of first, second and third ingredients is less than 90 wt./wt.% of the intermediate formulation.
CA002364610A 1999-03-19 2000-03-10 Pharmaceutical solubilized in aerosol propellant Expired - Fee Related CA2364610C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/272,563 US6350432B1 (en) 1999-03-19 1999-03-19 Pressurized container having an aerosolized pharmaceutical composition
US09/272,563 1999-03-19
US09/388,344 US6315984B1 (en) 1999-03-19 1999-09-03 Pressurized container having an aerosolized pharmaceutical composition
US09/388,344 1999-09-03
PCT/CA2000/000260 WO2000056291A1 (en) 1999-03-19 2000-03-10 Pharmaceutical solubilized in aerosol propellant

Publications (2)

Publication Number Publication Date
CA2364610A1 true CA2364610A1 (en) 2000-09-28
CA2364610C CA2364610C (en) 2006-12-19

Family

ID=26955601

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002364610A Expired - Fee Related CA2364610C (en) 1999-03-19 2000-03-10 Pharmaceutical solubilized in aerosol propellant

Country Status (6)

Country Link
EP (1) EP1162958A1 (en)
AU (1) AU766745B2 (en)
CA (1) CA2364610C (en)
MX (1) MXPA01009466A (en)
NZ (1) NZ514319A (en)
WO (1) WO2000056291A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
US6375975B1 (en) * 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
US6451286B1 (en) * 1998-12-21 2002-09-17 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
US7087215B2 (en) 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
US20030035774A1 (en) * 2001-07-18 2003-02-20 Adjei Akwete L. Salt/ion pair medicinal aerosol formulation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9007052D0 (en) * 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
US5230884A (en) * 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation

Also Published As

Publication number Publication date
NZ514319A (en) 2002-11-26
MXPA01009466A (en) 2002-05-14
WO2000056291A1 (en) 2000-09-28
EP1162958A1 (en) 2001-12-19
CA2364610C (en) 2006-12-19
AU3140000A (en) 2000-10-09
AU766745B2 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
CA2382535A1 (en) Mixed micellar pharmaceutical delivery system and method of preparation
NZ512188A (en) Micelle aerosol formulations for buccal and pulmonary application
AU784676B2 (en) Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces
US5929019A (en) Cleansing composition with separately dispensed cleansing base and benefit base wherein benefit base also comprises surfactant
CA2353847A1 (en) Pulmonary drug delivery
JP2002532536A5 (en)
JP4004228B2 (en) Foaming skin cleansing products
DK1053011T3 (en) Mixed micelle system for administering drug substances and process for their preparation
NZ509418A (en) Pharmaceutical formulations for aerosols with two or more active substances
WO2002000820A1 (en) Stable foam for use in disposable wipe
CA2383724A1 (en) Drug delivery system using membrane mimetics
AR021922A1 (en) PHARMACEUTICAL FORMULATIONS IN AEROSOL CONTAINING FLUOROALCANS, BUDESONIDO AND FORMOTEROL.
JP2003522096A5 (en)
NZ205846A (en) Galenic compositions containing calcitonin
AU1852000A (en) Large molecule drug delivery system using aerosolized membrane-mimetic amphiphiles
AR021921A1 (en) PHARMACEUTICAL FORMULATIONS IN AEROSOL CONTAINING FLUOROALCANS AND BUDESONIDO.
CA2364610A1 (en) Pharmaceutical solubilized in aerosol propellant
DK0693926T3 (en) New pharmaceutical composition for preparation of a stable powder containing a combination of acetylsalicylic acid and metoclopramide as active ingredient.
NZ332497A (en) Pharmaceutical composition having a carrier system containing a combination of an alkylene glycol and unsaturated fatty acid alcohol as the solvent and a stiffening agent
CA2229286A1 (en) Mixed micellar delivery system and method of preparation
IE56601B1 (en) Galenic compositions comprising calcitonin and their use
IE56602B1 (en) Galenic compositions comprising calcitonin and their use

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180312